Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 351 to 400 of 855 results for end of life

  1. Bisphosphonates for treating osteoporosis (TA464)

    Evidence-based recommendations on the bisphosphonates alendronic acid, ibandronic acid, risedronate sodium and zoledronic acid for treating osteoporosis.

  2. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel) and ustekinumab (Stelara) for plaque psoriasis in children and young people.

  3. Percutaneous image-guided cryoablation of peripheral neuroma for chronic pain (HTG652)

    Evidence-based recommendations on percutaneous image-guided cryoablation of peripheral neuroma for chronic pain. This involves using a needle-like probe to freeze and destroy small parts of nerves in neuromas to stop the pain signals.

  4. Caval valve implantation for tricuspid regurgitation (HTG726)

    Evidence-based recommendations on caval valve implantation for tricuspid regurgitation in adults. This involves implanting valves into 1 or both caval veins without disturbing the tricuspid valve.

  5. Endoscopic augmentation of the lower oesophageal sphincter using hydrogel implants for the treatment of gastro-oesophageal reflux disease (HTG142)

    Evidence-based recommendations on endoscopic augmentation of the lower oesophageal sphincter using hydrogel implants for gastro-oesophageal reflux. This involves inserting hydrogel implants into the wall of the oesophagus to narrow the entrance to the stomach and help prevent reflux.

  6. Osteoarthritis in over 16s: diagnosis and management (NG226)

    This guideline covers the diagnosis, assessment and non-surgical management of osteoarthritis. It aims to improve management of osteoarthritis and the quality of life for people with osteoarthritis.

  7. Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)

    Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.

  8. Recognising that a child or young person may be dying:- What signs and symptoms indicate that a child or young person with a life-limiting condition is likely to die within hours or days?

    dying:- What signs and symptoms indicate that a child or young person with a life-limiting condition is likely to die within hours or...

  9. Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome (TA139)

    Evidence-based recommendations on continuous positive airway pressure for treating obstructive sleep apnoea/hypopnoea syndrome in adults.

  10. NICE glossary

    The NICE glossary provides brief definitions and explanations of terms used on the website. The terms describe how NICE works and how its guidance is produced.

  11. Joint distraction for knee osteoarthritis without alignment correction (HTG381)

    Evidence-based recommendations on joint distraction for knee osteoarthritis without alignment correction. This involves fixing a metal frame around the knee to take weight off the joint and encourage the cartilage to repair itself.

  12. Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms (TA934)

    Evidence-based recommendations on foslevodopa–foscarbidopa (Produodopa) for treating advanced Parkinson’s with motor symptoms in adults.

  13. Tocilizumab for treating giant cell arteritis (TA518)

    Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults.

  14. Infracoccygeal sacropexy using mesh to repair uterine prolapse (HTG443)

    Evidence-based recommendations on infracoccygeal sacropexy using mesh to repair uterine prolapse in women. This involves attaching mesh from the buttocks to the top of the vagina to hold the uterus in place.

  15. Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)

    Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.

  16. Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation (TA798)

    Evidence-based recommendations on durvalumab (Imfinzi) for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults.

  17. Iptacopan for treating paroxysmal nocturnal haemoglobinuria (TA1000)

    Evidence-based recommendations on iptacopan (Fabhalta) for treating paroxysmal nocturnal haemoglobinuria in adults.

  18. Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)

    Evidence-based recommendations on continuous subcutaneous insulin infusion (insulin pump therapy) for treating type 1 diabetes in adults and children.

  19. Bringing our guidance together by topic

    We’re bringing our guidance together by topic, so that it’s all in one place, clearer to understand and easier to use.

  20. Secukinumab for treating active ankylosing spondylitis (TA407)

    Evidence-based recommendations on secukinumab (Cosentyx) for treating active ankylosing spondylitis.

  21. Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell carcinoma in adults.

  22. Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M (HTG292)

    Evidence-based recommendations on 3 electroencephalography (EEG)-based depth of anaesthesia monitors for assessing a patient’s response to anaesthetic drugs during surgery. The monitors are Bispectral Index (BIS), E-Entrophy and Narcotrend-Compact M.

  23. Chronic heart failure in adults: diagnosis and management (NG106)

    This guideline covers diagnosing and managing chronic heart failure in people aged 18 and over. It aims to improve diagnosis and treatment to increase the length and quality of life for people with heart failure.

  24. Balloon cryoablation for squamous dysplasia of the oesophagus (HTG560)

    Evidence-based recommendations on balloon cryoablation for squamous dysplasia of the oesophagus. This involves using a balloon filled with cold gas to destroy abnormal cells.

  25. Percutaneous mitral valve annuloplasty (HTG225)

    Evidence-based recommendations on percutaneous mitral valve annuloplasty. This involves inserting a catheter into a large vein in the groin or neck and passing through to the heart. A device is placed into a large vein that sits next to the mitral valve to constrict the valve, with the aim of making it close properly.

  26. Managing glioma: early referral to palliative care for glioblastoma:- Does early referral to palliative care improve outcomes for people with glioblastomas in comparison with standard oncology care?

    neurological impairment. These can significantly impact on their quality of life, function and psychological wellbeing. Their caregivers...

  27. Lung cancer: diagnosis and management (NG122)

    This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up.

  28. Romosozumab for treating severe osteoporosis (TA791)

    Evidence-based recommendations on romosozumab (EVENITY) for severe osteoporosis in people after menopause who are at high risk of fracture.

  29. Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia in adults.

  30. Perinatal palliative care:- What impact does timely perinatal palliative care have on the experience of bereaved parents?

    this is important:- Parents with a baby that is diagnosed antenatally with a life-limiting condition are increasingly being offered...

  31. Electrical stimulation of the lower oesophageal sphincter for treating gastro-oesophageal reflux disease (HTG395)

    Evidence-based recommendations on electrical stimulation of the lower oesophageal sphincter for treating gastro-oesophageal reflux disease. This involves applying low-energy electrical impulses to the sphincter to strengthen the muscle so that less reflux happens.

  32. Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (TA323)

    Evidence-based recommendations on erythropoiesis-stimulating agents (epoetin alfa [Eprex], epoetin beta [NeoRecormon], epoetin theta, epoeitin zeta [Retacrit] and darbepoetin alfa [Aranesp]) for treating anaemia in adults with cancer having chemotherapy.

  33. Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine (TA928)

    Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine, in adults.

  34. Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer (TA746)

    Evidence-based recommendations on nivolumab (Opdivo) as a possible treatment for completely resected oesophageal or gastro-oesophageal junction cancer in adults.

  35. Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia (HTG329)

    Evidence-based recommendations on insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia. This involves pulling back the parts of the prostate that are pressing on the urethra so that it's no longer blocked.

  36. Translaryngeal tracheostomy (HTG317)

    Evidence-based recommendations on translaryngeal tracheostomy (TLT). This involves passing a tube from inside the windpipe to outside the neck to aid breathing.

  37. Selinexor with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatments (TA970)

    Evidence-based recommendations on selinexor (Nexpovio) with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatments in adults.

  38. Acute kidney injury: prevention, detection and management (NG148)

    This guideline covers preventing, detecting and managing acute kidney injury in children, young people and adults. It aims to improve assessment and detection by non-specialists, and specifies when people should be referred to specialist services. This will improve early recognition and treatment, and reduce the risk of complications in people with acute kidney injury.

  39. Ocrelizumab for treating primary progressive multiple sclerosis (TA585)

    Evidence-based recommendations on ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis in adults.

  40. Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)

    Evidence-based recommendations on lenvatinib (Kisplyx) with everolimus for previously treated advanced renal cell carcinoma in adults.

  41. Decision-making and mental capacity (NG108)

    This guideline covers decision-making in people 16 years and over who may lack capacity now or in the future. It aims to help health and social care practitioners support people to make their own decisions where they have the capacity to do so. It also helps practitioners to keep people who lack capacity at the centre of the decision-making process.

  42. Intermediate care including reablement (QS173)

    This quality standard covers referral and assessment for intermediate care and how to deliver the service. It covers bed-based intermediate care, crisis response, home-based intermediate care and reablement. It describes high-quality care in priority areas for improvement. It does not cover rehabilitation for specific conditions.

  43. Holmium laser prostatectomy (HTG5)

    Evidence-based recommendations on holmium laser prostatectomy. This involves using heat from a laser to break down the extra tissue in the prostate.

  44. Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer (TA903)

    Evidence-based recommendations on darolutamide (Nubeqa) with androgen deprivation therapy and docetaxel for hormone-sensitive metastatic prostate cancer in adults.

  45. Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)

    Evidence-based recommendations on secukinumab (Cosentyx) for active moderate to severe hidradenitis suppurativa (acne inversa) in adults.

  46. Suspected sepsis in people aged 16 or over: recognition, assessment and early management (NG253)

    This guideline covers the recognition, diagnosis and early management of suspected sepsis in people aged 16 or over who are not and have not recently been pregnant. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.

  47. Targeted muscle reinnervation for managing limb amputation pain (HTG750)

    Evidence-based recommendations on targeted muscle reinnervation for managing limb amputation pain. This involves attaching nerves that were cut during limb amputation to other nerves in nearby muscles.

  48. Diverticular disease: diagnosis and management (NG147)

    This guideline covers the diagnosis and management of diverticular disease in people aged 18 years and over. It aims to improve diagnosis and care and help people get timely information and advice, including advice about symptoms and when to seek help.

  49. Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults (NG215)

    This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants in primary and secondary care.